← Back to headlines
Dupixent Approved as First Biologic for Pediatric CSU Patients
Sanofi and Regeneron's drug Dupixent has received approval, becoming the first biologic treatment available for children under 12 suffering from chronic spontaneous urticaria (CSU).
23 Apr, 05:26 — 23 Apr, 05:26
Sources
Showing 1 of 1 sources
